Gyre Therapeutics GYRE
$4.76 +$0.75 (+18.70%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $4.76 0.00%
Open$4.56
Prev close$4.01
Day range$4.08 – $4.79
Volume359.7K
Market cap$504.72M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$29.11M-2.1% YoY
Operating profit-$13.86M-518.8% YoY
Net profit-$14.27M-537.9% YoY
Diluted EPS-$0.12-300.0% YoY
Free cash flow-$18.01M-130.0% YoY
Operating cash flow-$16.73M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin93.8%
Operating margin-13.9%
Net margin-18.1%
Return on equity-19.9%
Return on assets-11.3%
Return on invested capital-20.3%
Current ratio4.26
Liabilities / assets28.5%
Cash & investments$74.80M
Total debt$2.03M
Net cash (debt)$72.76M
Where the revenue comes from
Quarter 2026/Q2
By business line
Income statement
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $29.11M | $22.52M | $116.59M | $37.20M | $30.56M |
| Total Operating Revenue | $29.11M | $22.52M | $116.59M | $37.20M | $30.56M |
| Cost of Revenue | $2.21M | $1.23M | $5.42M | $1.74M | $1.63M |
| Gross Profit | $26.90M | $21.29M | $111.17M | $35.45M | $28.94M |
| Operating Expense | $40.76M | $28.09M | $99.68M | $35.33M | $22.01M |
| Selling and Admin Expenses | $21.62M | $21.36M | $85.98M | $30.52M | $19.65M |
| -Selling & Marketing Expense | $13.75M | $14.14M | $65.18M | $23.82M | $15.33M |
| -General & Admin Expense | $7.87M | $7.22M | $20.80M | $6.70M | $4.32M |
| Research & Development | $19.14M | $6.74M | $13.70M | $4.82M | $2.36M |
| Operating Profit | -$13.86M | -$6.80M | $11.49M | $120,000.00 | $6.93M |
| Net Non-Operating Interest Income (Expense) | $740,000.00 | – | $1.75M | – | – |
| Non-Operating Interest Income | $740,000.00 | – | $1.75M | – | – |
| Other Income (Expense) | -$1.31M | -$2.44M | $1.20M | -$1.93M | $703,000.00 |
| Gain on Sale of Security | $132,000.00 | $89,000.00 | $2.71M | $263,000.00 | -$23,000.00 |
| Special Income (Charges) | -$502,000.00 | -$2.55M | -$4,000.00 | -$2,000.00 | -$1,000.00 |
| -Less:Restructuring and Mergern & Acquisition | $502,000.00 | $2.55M | – | – | – |
| Other Non-Operating Income (Expenses) | -$943,000.00 | $29,000.00 | -$1.51M | -$2.19M | $727,000.00 |
| Pretax Profit | -$14.43M | -$9.24M | $14.44M | -$66,000.00 | $7.63M |
| Tax | -$164,000.00 | $621,000.00 | $4.56M | $1.30M | $1.69M |
| Net Profit | -$14.27M | -$9.86M | $9.88M | -$1.37M | $5.94M |
| Profit from Continuing Operations | -$14.27M | -$9.86M | $9.88M | -$1.37M | $5.94M |
| Minority Interests | -$3.67M | -$1.17M | $4.85M | $357,000.00 | $2.33M |
| Net Income to Parent Company | -$10.61M | -$8.69M | $5.03M | -$1.72M | $3.61M |
| Preferred Stock Dividends | $1.06M | – | – | – | – |
| Net Income to Common Stockholders | -$11.66M | -$8.69M | $5.03M | -$1.72M | $3.61M |
| Basic EPS | -$0.12 | -$0.10 | $0.06 | -$0.02 | $0.04 |
| Diluted EPS | -$0.12 | -$0.10 | $0.02 | -$0.02 | $0.03 |
| -Gain on Sale of Property/Plant/Equipment | – | – | -$4,000.00 | -$2,000.00 | -$1,000.00 |
Balance sheet
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total Assets | $199.26M | $162.02M | $166.13M | $166.13M | $159.38M |
| Total Current Assets | $122.07M | $91.73M | $102.37M | $102.37M | $98.58M |
| Cash and Cash Equivalents & Short-Term Investments | $74.80M | $49.81M | $52.43M | $52.43M | $60.05M |
| -Cash and Cash Equivalents | $43.29M | $37.50M | $37.07M | $37.07M | $40.40M |
| -Short Term Investments | $31.51M | $12.31M | $15.36M | $15.36M | $19.65M |
| Receivables | $28.25M | $26.81M | $36.95M | $36.95M | $26.80M |
| -Accounts Receivable | $27.76M | $22.76M | $31.08M | $31.08M | $25.88M |
| -Notes Receivable | $232,000.00 | $3.82M | $5.64M | $5.64M | $693,000.00 |
| -Other Receivables | $255,000.00 | $230,000.00 | $230,000.00 | $230,000.00 | $230,000.00 |
| Inventory | $11.43M | $11.35M | $10.17M | $10.17M | $8.85M |
| Other Current Assets | $7.60M | $3.76M | $1.49M | $1.49M | – |
| Total Non-Current Assets | $77.18M | $70.28M | $63.76M | $63.76M | $60.81M |
| Net PPE | $27.28M | $23.57M | $24.73M | $24.73M | $23.61M |
| -Gross PPE | $39.98M | $31.74M | $32.31M | $32.31M | $30.54M |
| -Accumulated Depreciation | -$12.70M | -$8.17M | -$7.58M | -$7.58M | -$6.93M |
| Investments and Advances | $28.44M | $29.42M | $23.52M | $23.52M | $20.32M |
| -Available for Sale Securities | $28.44M | $29.42M | $23.52M | $23.52M | $20.32M |
| Non-Current Prepaid Assets | $302,000.00 | – | – | – | – |
| Goodwill and Other Intangible Assets | $4.53M | $4.63M | $6.15M | $6.15M | $4.85M |
| -Other Intangible Assets | $4.53M | $4.63M | $6.15M | $6.15M | $4.85M |
| Non-Current Deferred Assets | $9.28M | $7.72M | $6.87M | $6.87M | $6.71M |
| Other Non-Current Assets | $7.34M | $4.94M | $2.49M | $2.49M | $5.32M |
| Total Liabilities | $56.77M | $25.03M | $23.85M | $23.85M | $21.97M |
| Total Current Liabilities | $28.66M | $19.79M | $18.29M | $18.29M | $15.91M |
| Payables | $11.50M | $7.16M | $5.72M | $5.72M | $7.13M |
| -Accounts Payable | $1.24M | $265,000.00 | $124,000.00 | $124,000.00 | $556,000.00 |
| -Total Tax Payable | $2.35M | $3.13M | $2.94M | $2.94M | $2.65M |
| -Due to Related Parties Current | $5.09M | $226,000.00 | $227,000.00 | $227,000.00 | $228,000.00 |
| -Other Payable | $2.83M | $3.54M | $2.43M | $2.43M | $3.70M |
| Current Accrued Expenses | $15.49M | $11.76M | $11.81M | $11.81M | $7.96M |
| Short-Term Debt and Capital Lease Obligation | $1.39M | $751,000.00 | $636,000.00 | $636,000.00 | $626,000.00 |
| -Current Capital Lease Obligation | $1.39M | $751,000.00 | $636,000.00 | $636,000.00 | $626,000.00 |
| Current Deferred Liabilities | $189,000.00 | $99,000.00 | $111,000.00 | $111,000.00 | $154,000.00 |
| Total Non-Current Liabilities | $28.10M | $5.24M | $5.56M | $5.56M | $6.06M |
| Long Term Debt and Capital Lease Obligation | $2.03M | $72,000.00 | $303,000.00 | $303,000.00 | $539,000.00 |
| -Long Term Capital Lease Obligation | $2.03M | $72,000.00 | $303,000.00 | $303,000.00 | $539,000.00 |
| Derivative Product Liabilities | $2.74M | $2.87M | $2.96M | $2.96M | $3.22M |
| Non-Current Deferred Liabilities | $829,000.00 | $840,000.00 | $852,000.00 | $852,000.00 | $866,000.00 |
| Convertible preferred securities | $22.43M | – | – | – | – |
| Other Non-Current Liabilities | $70,000.00 | $1.46M | $1.45M | $1.45M | $1.43M |
| Total Equity | $142.49M | $136.99M | $142.28M | $142.28M | $137.42M |
| Stockholders' Equity | $107.93M | $101.31M | $106.03M | $106.03M | $101.92M |
| Capital Stock | $106,000.00 | $91,000.00 | $91,000.00 | $91,000.00 | $91,000.00 |
| -Common Stock | $106,000.00 | $91,000.00 | $91,000.00 | $91,000.00 | $91,000.00 |
| Additional Paid-In Capital | $240.64M | $174.65M | $172.05M | $172.05M | $167.13M |
| Retained Earnings | -$137.96M | -$77.67M | -$68.43M | -$68.43M | -$66.70M |
| Gains/Losses Not Affecting Retained Earnings | $5.14M | $4.23M | $2.32M | $2.32M | $1.40M |
| Minority Interests | $34.56M | $35.68M | $36.25M | $36.25M | $35.50M |
| Prepaid Assets | – | – | $1.34M | $1.34M | $2.87M |
Cash flow
| Line item | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$16.73M | $3.18M | $1.01M | -$5.63M | $14.24M |
| Net cash flow from continuing operations | -$16.73M | $3.18M | $1.01M | -$5.63M | $14.24M |
| Net Income from Continuing Operations | -$22.99M | -$9.86M | $9.88M | -$1.37M | $8.54M |
| Gain/Loss from Continuing Operations | -$68,000.00 | -$52,000.00 | -$2.59M | -$241,000.00 | $42,000.00 |
| Depreciation & Depletion & Amortization | $1.48M | $672,000.00 | $2.52M | $695,000.00 | $281,000.00 |
| Deferred Tax | -$1.43M | -$738,000.00 | -$1.11M | -$87,000.00 | -$531,000.00 |
| Other Non-Cash Items | -$328,000.00 | $864,000.00 | $791,000.00 | $277,000.00 | -$474,000.00 |
| Change in Working Capital | $4.56M | $9.51M | -$15.58M | -$9.47M | $5.81M |
| -Change in Receivables | -$1.00M | $10.48M | -$11.95M | -$9.67M | -$1.19M |
| -Change in Inventory | $94,000.00 | -$1.02M | -$3.63M | -$1.21M | $72,000.00 |
| -Change in Prepaid Assets | $2.98M | -$912,000.00 | -$206,000.00 | -$509,000.00 | $1.01M |
| -Change in Payables and Accrued Expense | $3.03M | $966,000.00 | $1.00M | $2.21M | -$2.33M |
| -Change in Other Current Liabilities | -$536,000.00 | $0.00 | -$791,000.00 | -$283,000.00 | $51,000.00 |
| Net cash flow from investing | $9.76M | -$3.06M | -$474,000.00 | $1.85M | -$5.64M |
| Net Cash Flow from Continuing Investing Activities | $9.76M | -$3.06M | -$474,000.00 | $1.85M | -$5.64M |
| Net PPE Purchase and Sale | -$255,000.00 | -$172,000.00 | -$1.16M | -$133,000.00 | -$589,000.00 |
| Net Intangibles Purchase and Sale | -$1.02M | -$5,000.00 | -$733,000.00 | $4,000.00 | -$15,000.00 |
| Net Investment Purchase and Sale | $11.04M | -$2.88M | $1.42M | $1.98M | -$5.04M |
| Financing Cash Flow | -$8,000.00 | $21,000.00 | $24.38M | $318,000.00 | $2.47M |
| Net Cash Flow from Continuing Financing Activities | -$8,000.00 | $21,000.00 | $24.38M | $318,000.00 | $2.47M |
| Net Common Stock Issuance | $0.00 | $0.00 | $23.51M | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $200,000.00 | $21,000.00 | $2.36M | $318,000.00 | $50,000.00 |
| Ending Cash Balance | $43.29M | $37.50M | $37.07M | $37.07M | $40.40M |
| Net Change in Cash | -$6.98M | $146,000.00 | $24.91M | -$3.46M | $11.07M |
| Beginning Cash Balance | $37.50M | $37.07M | $11.81M | $40.40M | $56.37M |
| Effect of Exchange Rate Changes | $643,000.00 | $285,000.00 | $343,000.00 | $127,000.00 | $206,000.00 |
| Free Cash Flow | -$18.01M | $3.00M | -$913,000.00 | -$5.77M | $13.63M |
| Net Business Purchase and Sale | – | – | $0.00 | $0.00 | – |
| Net Other Financing Charges | – | – | -$1.49M | $0.00 | $2.42M |
No comments yet — be the first to weigh in on GYRE.
Sign in to join the discussion.